Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 103,452 shares at $68.69 ($7.2M) on 2025-12-29, disclosed to the SEC on 2025-12-30.
Scheduled sale ($7.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.69 | 16,545 | $1.1M | 15.9% |
| 2 | $68.69 | 16,545 | $1.1M | 15.9% |
| 3 | $69.33 | 35,181 | $2.4M | 34.1% |
| 4 | $69.33 | 35,181 | $2.4M | 34.1% |
| Total | $69.13 avg | 103,452 | $7.2M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |
| ARWR | SELL | 2025-04-11 | $1.9M | — | Filing → |